Rain Oncology (NASDAQ:RAIN) Now Covered by Analysts at Mizuho

Mizuho began coverage on shares of Rain Oncology (NASDAQ:RAINGet Rating) in a research report sent to investors on Monday, The Fly reports. The brokerage issued a buy rating and a $18.00 price objective on the stock.

Other research analysts have also recently issued reports about the company. Lifesci Capital reaffirmed an outperform rating on shares of Rain Oncology in a research note on Friday, January 6th. HC Wainwright raised their price objective on Rain Oncology from $10.00 to $12.00 in a research note on Friday, November 11th. EF Hutton Acquisition Co. I began coverage on Rain Oncology in a research note on Thursday, January 5th. They set a buy rating and a $16.00 price objective on the stock. Finally, Citigroup reduced their price objective on Rain Oncology from $30.00 to $29.00 and set a buy rating on the stock in a research note on Wednesday, November 23rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of Buy and a consensus target price of $16.88.

Rain Oncology Stock Up 3.8 %

RAIN opened at $9.85 on Monday. The stock has a market cap of $261.67 million, a PE ratio of -3.68 and a beta of -0.01. Rain Oncology has a 52 week low of $2.15 and a 52 week high of $14.48. The business’s fifty day simple moving average is $8.04 and its 200 day simple moving average is $6.72.

Rain Oncology (NASDAQ:RAINGet Rating) last announced its quarterly earnings data on Thursday, November 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. As a group, equities analysts anticipate that Rain Oncology will post -2.46 earnings per share for the current year.

Insider Transactions at Rain Oncology

In other news, Director Franklin M. Berger bought 45,000 shares of the company’s stock in a transaction dated Monday, November 21st. The stock was bought at an average cost of $7.80 per share, for a total transaction of $351,000.00. Following the completion of the acquisition, the director now owns 928,207 shares in the company, valued at approximately $7,240,014.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director Franklin M. Berger acquired 45,000 shares of the stock in a transaction on Monday, November 21st. The stock was acquired at an average cost of $7.80 per share, for a total transaction of $351,000.00. Following the completion of the acquisition, the director now directly owns 928,207 shares of the company’s stock, valued at approximately $7,240,014.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Bvf Partners L. P/Il acquired 1,710,358 shares of the stock in a transaction on Tuesday, November 8th. The stock was bought at an average price of $5.83 per share, with a total value of $9,971,387.14. Following the completion of the acquisition, the insider now directly owns 2,870,985 shares of the company’s stock, valued at $16,737,842.55. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 2,727,570 shares of company stock worth $15,990,383. Company insiders own 21.90% of the company’s stock.

Institutional Trading of Rain Oncology

Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in shares of Rain Oncology by 8.4% during the first quarter. BlackRock Inc. now owns 803,211 shares of the company’s stock valued at $4,072,000 after purchasing an additional 62,340 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Rain Oncology by 2.7% during the first quarter. Vanguard Group Inc. now owns 521,033 shares of the company’s stock valued at $2,641,000 after purchasing an additional 13,758 shares during the last quarter. State Street Corp lifted its holdings in shares of Rain Oncology by 42.0% during the first quarter. State Street Corp now owns 191,801 shares of the company’s stock valued at $972,000 after purchasing an additional 56,723 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Rain Oncology by 69.0% during the first quarter. Northern Trust Corp now owns 121,824 shares of the company’s stock valued at $618,000 after purchasing an additional 49,727 shares during the last quarter. Finally, Citadel Advisors LLC lifted its holdings in shares of Rain Oncology by 549.0% during the third quarter. Citadel Advisors LLC now owns 67,250 shares of the company’s stock valued at $328,000 after purchasing an additional 56,888 shares during the last quarter. 82.91% of the stock is currently owned by hedge funds and other institutional investors.

Rain Oncology Company Profile

(Get Rating)

Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.

Featured Stories

The Fly logo

Analyst Recommendations for Rain Oncology (NASDAQ:RAIN)

Receive News & Ratings for Rain Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Oncology and related companies with MarketBeat.com's FREE daily email newsletter.